Bulk Pharmaceutical API Sources for MIOSTAT

Bulk Pharmaceutical API Sources for MIOSTAT

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		C4382_SIGMA
Sigma-Aldrich		C2409_ALDRICH
TCI (Tokyo Chemical Industry)		C0596
Molport		MolPort-003-666-136
Amadis Chemical		A828807

MIOSTAT Bulk API Sourcing: Patent Landscape and Supplier Analysis

Last updated: February 19, 2026

This report analyzes the patent landscape and identifies key bulk Active Pharmaceutical Ingredient (API) suppliers for MIOSTAT, a drug targeting intraocular pressure. The analysis focuses on patent expirations, generic entry potential, and the competitive sourcing environment.

What is MIOSTAT and What is its Therapeutic Application?

MIOSTAT is a brand name for carbachol, a parasympathomimetic miotic agent. It is primarily used ophthalmologically to induce miosis (pupillary constriction) during ophthalmic surgery, specifically in cataract and iridectomy procedures. Carbachol acts by stimulating muscarinic cholinergic receptors in the iris sphincter muscle, leading to pupillary contraction. It is administered as an intraocular solution.

What is the Patent Status of MIOSTAT (Carbachol)?

Carbachol, as a chemical entity, was developed in the mid-20th century and its primary patents have long since expired. As a well-established, off-patent compound, the intellectual property landscape for MIOSTAT is characterized by the absence of active composition-of-matter patents covering the carbachol molecule itself.

However, secondary patents can exist for specific formulations, manufacturing processes, or novel delivery systems. For instance, patents might cover:

• Specific concentrations: While carbachol is a known entity, a patent could exist for a unique therapeutic concentration of the drug in an ophthalmic solution.
• Excipients and formulations: Patents may protect novel combinations of excipients that improve stability, solubility, or penetration of carbachol.
• Manufacturing processes: Innovative or cost-effective methods for synthesizing or purifying carbachol could be patent-protected.
• Sterilization techniques: Methods for ensuring the sterility of intraocular solutions are crucial and could be subject to patent.
• Delivery devices: While MIOSTAT itself is an API, its ultimate delivery form might be subject to patents, though this would not impact bulk API sourcing.

A thorough patent search for "carbachol ophthalmic solution," "miotic agent formulation," and specific manufacturing pathways would be necessary to identify any existing, active secondary patents that could impact market entry or sourcing strategies. The absence of primary composition-of-matter patents for carbachol itself is the dominant factor, enabling generic competition.

Who are the Key Bulk API Suppliers for MIOSTAT (Carbachol)?

The market for carbachol API is characterized by a number of global manufacturers, primarily based in Asia, that supply to generic pharmaceutical companies worldwide. These suppliers compete on price, quality, and regulatory compliance. Due to carbachol’s long history and off-patent status, it is considered a commodity API, leading to a competitive pricing environment.

Key suppliers often possess Good Manufacturing Practice (GMP) certifications and are audited by regulatory agencies like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). The following table lists some of the prominent manufacturers of carbachol API. Specific details regarding production volume and market share are proprietary and not publicly disclosed.

Supplier Name	Location(s)	Key Certifications (Likely)	Notes
Akorn, Inc.	United States	FDA GMP	While primarily a finished dosage form manufacturer, Akorn may have internal API manufacturing capabilities or strong relationships with API producers.
Sterile Pharmaceuticals	United States	FDA GMP	Similar to Akorn, focus is on finished product, but sourcing of APIs is critical to their operations.
Alcon Laboratories, Inc.	Switzerland	FDA GMP, EMA GMP	Global leader in eye care, likely has internal API sourcing or manufacturing for its carbachol-containing products.
Hikma Pharmaceuticals	United Kingdom (Global Operations)	FDA GMP, EMA GMP	Operates a significant generics business and likely sources or manufactures carbachol API for its ophthalmic product lines.
Teva Pharmaceutical Industries Ltd.	Israel	FDA GMP, EMA GMP	One of the largest generic drug manufacturers globally, Teva undoubtedly sources or produces carbachol API for its extensive product portfolio.
Sun Pharmaceutical Industries Ltd.	India	FDA GMP, EMA GMP	Major Indian pharmaceutical company with a strong generics and API manufacturing presence.
Dr. Reddy's Laboratories	India	FDA GMP, EMA GMP	Another leading Indian API and finished dosage form manufacturer with a global reach.
Lupin Limited	India	FDA GMP, EMA GMP	Significant player in the global generics market, with substantial API manufacturing capacity.
Divi's Laboratories	India	FDA GMP, EMA GMP	While not directly manufacturing finished ophthalmic drugs, Divi's is a major producer of APIs and could be a supplier for carbachol.
Shandong Xinhua Pharmaceutical Co., Ltd.	China	FDA GMP, SFDA GMP	A large Chinese pharmaceutical enterprise with extensive API production capabilities, often a significant global supplier for various APIs.
Hubei Biocause Pharmaceutical Co., Ltd.	China	CFDA GMP	Another Chinese manufacturer known for producing a wide range of APIs, likely including carbachol.

Note: This list is not exhaustive and is based on general industry knowledge of API manufacturers serving the ophthalmic segment. Specific supplier relationships for branded MIOSTAT and generic carbachol products can vary. Direct engagement with API manufacturers is recommended for precise sourcing information.

What are the Regulatory Considerations for API Sourcing?

Sourcing bulk API for pharmaceutical products, including carbachol, is subject to stringent regulatory oversight. Key considerations include:

• Good Manufacturing Practice (GMP): The API must be manufactured in compliance with current GMP standards as defined by regulatory authorities such as the FDA (21 CFR Parts 210 & 211) and EMA. This ensures consistent quality, purity, and safety.
• Drug Master File (DMF) / Active Substance Master File (ASMF): API manufacturers typically file a DMF (in the US) or ASMF (in Europe) with regulatory agencies. This confidential document details the manufacturing process, quality control, and stability data of the API. Finished dosage form manufacturers reference these filings in their drug applications.
• Certificate of Analysis (CoA): Each batch of API must be accompanied by a CoA confirming that it meets predefined specifications for identity, purity, potency, and absence of impurities.
• Impurity Profiling: Thorough characterization and control of impurities, including genotoxic impurities, are critical. Regulatory agencies require detailed information on process impurities and degradation products.
• Supply Chain Security: Ensuring the integrity of the API supply chain, from raw material sourcing by the API manufacturer to delivery to the finished product manufacturer, is essential to prevent counterfeiting and contamination.
• Audits: Finished dosage form manufacturers are responsible for qualifying and auditing their API suppliers to ensure ongoing compliance with GMP and other regulatory requirements.
• Pharmacopoeial Standards: The API must meet the specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP) or the European Pharmacopoeia (Ph. Eur.).

What are the Market Dynamics and Competition for Carbachol API?

The market for carbachol API is a mature and highly competitive segment of the pharmaceutical industry. Several factors define its dynamics:

• Genericization: Carbachol is a well-established drug with no active composition-of-matter patent protection. This has led to widespread generic availability of finished dosage forms, driving demand for cost-effective API.
• Price Sensitivity: Due to the generic nature of the product and the availability of multiple API suppliers, price is a significant competitive factor. Manufacturers of finished carbachol products, particularly generic versions, seek the lowest feasible API cost while maintaining quality standards.
• Supplier Base: The majority of carbachol API suppliers are located in India and China. These regions offer a competitive manufacturing cost base, which contributes to the overall pricing structure. Companies in these regions often have large-scale production capabilities.
• Quality and Regulatory Compliance: While price is important, the ability of API suppliers to meet stringent GMP requirements and provide comprehensive regulatory documentation (DMF/ASMF, CoAs) is non-negotiable. Regulatory hurdles can act as a barrier to entry for less sophisticated manufacturers.
• Demand Drivers: The primary demand for carbachol API is driven by the ophthalmic surgical market. The prevalence of procedures like cataract surgery, which requires induced miosis, dictates the baseline demand.
• Consolidation and Partnerships: In the API sector, there can be consolidation among manufacturers or strategic partnerships formed between API producers and large finished dosage form companies to ensure a stable supply chain and favorable pricing.
• Emerging Markets: Growth in healthcare infrastructure and surgical procedures in emerging markets can contribute to increased demand for carbachol API.

The competitive landscape is thus characterized by a large number of suppliers vying for business based on a balance of cost, quality assurance, and regulatory adherence. Any new entrant into the carbachol API market would need to demonstrate significant cost advantages or a superior quality proposition to gain market share.

Key Takeaways

• MIOSTAT (carbachol) API is a commodity with no active composition-of-matter patents, enabling broad generic competition.
• Key API suppliers are primarily located in India and China, leveraging cost advantages alongside stringent GMP compliance.
• Regulatory adherence, including GMP certification and DMF/ASMF filings, is critical for API sourcing.
• The market is price-sensitive, driven by the demand for cost-effective generic ophthalmic solutions.
• Quality assurance and a reliable supply chain are paramount for finished dosage form manufacturers.

Frequently Asked Questions

1. Are there any patent barriers to manufacturing generic carbachol API? No, the primary composition-of-matter patents for carbachol have long expired. Potential barriers could arise from patents on specific manufacturing processes or novel formulations, but these are typically addressable through independent development.

2. Which countries are the primary sources for carbachol API? India and China are the dominant manufacturing hubs for carbachol API, offering competitive pricing and large-scale production capabilities.

3. What are the essential quality certifications required for carbachol API suppliers? Suppliers must adhere to current Good Manufacturing Practices (cGMP) as mandated by regulatory bodies like the FDA and EMA. They should also provide detailed Certificates of Analysis (CoA) for each batch.

4. How does the price of carbachol API compare to newer ophthalmic drugs? As an off-patent, widely produced API, carbachol is significantly less expensive than patented, novel ophthalmic drugs. Its price is indicative of a mature commodity market.

5. What due diligence is necessary when selecting a carbachol API supplier? Thorough due diligence includes verifying GMP compliance through audits, reviewing regulatory filings (DMF/ASMF), assessing impurity profiles, ensuring supply chain transparency, and confirming adherence to pharmacopoeial standards.

Citations

[1] U.S. Food and Drug Administration. (n.d.). 21 CFR Parts 210 & 211 - Current Good Manufacturing Practice For Finished Pharmaceuticals. U.S. Government Publishing Office. [2] European Medicines Agency. (n.d.). EudraLex - The Rules Governing Medicinal Products in the European Union. European Union. [3] United States Pharmacopeia. (n.d.). United States Pharmacopeia-National Formulary (USP-NF). U.S. Pharmacopeial Convention. [4] European Pharmacopoeia. (n.d.). European Pharmacopoeia (Ph. Eur.). European Directorate for the Quality of Medicines & HealthCare.